Longevity Papers Podcast

In this episode, we discuss five groundbreaking papers from longevitypapers.com on mechanisms of aging and potential interventions: 1) Enhanced non-enzymatic H2S generation via natural diallyl sulforated compounds extends lifespan and healthspan in mice (Cáliz-Molina et al., Cell Metabolism, December 2025, https://pubmed.ncbi.nlm.nih.gov/41421349/ ) - Diallyl sulforated compounds boost endogenous hydrogen sulfide, improving mitochondrial function, suppressing mTOR-related aging pathways, and restoring protein persulfidation in aged mice. This non-pharmacological approach addresses multiple hallmarks of aging. 2) Selective activation of NaV1.3 restores lymphatic contractility in aging and injury (Ruscic et al., Massachusetts General Hospital, December 2025, https://www.biorxiv.org/content/10.64898/2025.12.15.694318v1 ) - A newly identified voltage-gated sodium channel selectively expressed in lymphatic muscle can be pharmacologically activated to restore lymphatic pumping in aged mice, addressing a previously untargeted aging system critical for immunity and metabolic homeostasis. 3) Mitochondrial RNA cytosolic leakage drives the SASP (Victorelli et al., Mayo Clinic, December 2025, https://pubmed.ncbi.nlm.nih.gov/41392167/ ) - Beyond mtDNA, mitochondrial RNA leakage activates RIG-I and MDA5 sensors to drive senescence-associated inflammation. BAX/BAK deletion reduces SASP, suggesting RNA sensors as novel druggable targets. 4) Awakening intracellular immunity for functional HIV cure via CD4 T cell reprogramming (Lanna et al., University College London, January 2026, https://www.biorxiv.org/content/10.64898/2026.01.08.698387v1 ) - Transient CD4 T cell reprogramming activates antiviral telomere transfer programs that eliminate integrated HIV DNA, offering potential functional cure. Since HIV accelerates epigenetic aging by ~13 years, this is transformative for aging in HIV+ populations and may generalize to other age-related immune dysfunction. 5) Rapamycin exerts geroprotective effects by enhancing DNA damage resilience in human immune cells (Kell et al., University of Oxford, January 2026, https://pubmed.ncbi.nlm.nih.gov/41546123/ ) - First human mechanistic study of low-dose rapamycin shows direct genoprotection of aged T cells through reduced DNA lesional burden and p21 suppression. Off-patent, low-cost, and immediately clinically translatable. This podcast is AI generated and may contain errors.